Core Insights - Passage Bio, Inc. reported updated interim data from the upliFT-D study, indicating that PBFT02 shows robust and durable elevation in cerebrospinal fluid (CSF) progranulin (PGRN) levels and improvement in plasma neurofilament light chain (NfL), a biomarker for disease progression [1][5] - The company has completed dosing of Cohort 2 in the upliFT-D study and submitted an amended protocol to global trial sites and health authorities [2][5] - As of June 30, 2025, the company has a cash position of $57.6 million, which is expected to fund operations into the first quarter of 2027 [4] Recent Highlights - The dosing of Cohort 2 in the upliFT-D study was completed, with a total of four FTD-GRN patients treated [5] - Interim data showed that Dose 1 PBFT02 treatment resulted in a significant increase in CSF PGRN levels, with the first patient treated with Dose 2 showing substantial increases at one month post-treatment [5] - The company plans to initiate enrollment of Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) once the amended protocol is approved [2][5] Financial Results - Research and Development (R&D) expenses for Q2 2025 were $5.8 million, down from $10.4 million in Q2 2024 [13] - General and Administrative (G&A) expenses for Q2 2025 were $4.5 million, compared to $6.5 million in Q2 2024 [13] - The net loss for Q2 2025 was $9.4 million, or $2.96 per share, a decrease from a net loss of $16.0 million, or $5.09 per share, in Q2 2024 [13][19] Anticipated Upcoming Milestones - The company seeks regulatory feedback on the suspension-based manufacturing process comparability in the second half of 2025 [5] - Updated interim safety and biomarker data from Dose 2 is expected to be reported in the first half of 2026 [5] - Regulatory feedback on the registrational trial design in FTD-GRN is anticipated in the first half of 2026 [5]